Company intelligence / Profile preview
Kyungdong Pharmaceutical
Seoul, South Koreakdpharma.co.kr ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Kyungdong Pharmaceutical has developed and received approval for small molecule drugs such as clopidogrel camsylate (approved for thrombosis) and sibutramine sulfate (approved for obesity) in South Korea. The company maintains an active clinical pipeline in endocrinology, cardiovascular, metabolic, nervous system, and urinary indications with several diabetes and hypertension candidates in early clinical stages. Published literature describes the company's work in developing and optimizing formulations for drugs including dapagliflozin and metformin.
- Therapeutic areas
- NephrologyCardiovascularEndocrinologyInfectious DiseasesNeurologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Beyond the preview
Go deeper on Kyungdong Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kyungdong Pharmaceutical.